Insider · CIK 0001410677
Gregory J Divis
Files at AVDL (AVADEL PHARMACEUTICALS PLC). First filing Dec 10, 2024, latest Dec 10, 2024.
In brief
Gregory J Divis files SEC Form 4 as CEO and director at AVDL (AVADEL PHARMACEUTICALS PLC). Since Dec 10, 2024, Gregory J Divis has reported 1 open-market buy worth $100k and 0 open-market sells worth $0, the latest filed on Dec 10, 2024.
A track record needs three past buys with six months of prices behind them; Gregory J Divis has 0, so none is measured yet.
The newest scored trade: bought $100k of AVDL on Dec 6, 2024, filed Dec 10, 2024, scored 58 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | AVADEL PHARMACEUTICALS PLC | $100k 10,000 shares | - | - |
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Ordinary Shares | -211,105 | $21.00 | $4.4M | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Ordinary Sharesindirect: By Trust | -10,000 | $21.00 | $210k | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -150,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -100,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -100,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -400,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -500,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -310,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -350,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -600,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -310,000 | - | - | 0 | Feb 12, 2026 |
| Mar 5, 2025 | AVDL AVADEL PHARMACEUTICALS PLC | AGrant or award Ordinary Shares | +52,000 | $0.00 | $0 | 211,100 | Mar 7, 2025 |
| Mar 5, 2025 | AVDL AVADEL PHARMACEUTICALS PLC | AGrant or award Stock Option (Right to Buy)derivative | +310,000 | $0.00 | $0 | 310,000 | Mar 7, 2025 |
| Dec 6, 2024 | AVDL AVADEL PHARMACEUTICALS PLC | POpen-market purchase Ordinary Sharesindirect: By Trust | +9,598 | $9.98 | $96k | 9,598 | Dec 10, 2024 |
| Dec 9, 2024 | AVDL AVADEL PHARMACEUTICALS PLC | POpen-market purchase Ordinary Sharesindirect: By Trust | +402 | $9.82 | $3,948 | 10,000 | Dec 10, 2024 |
| Feb 20, 2024 | AVDL AVADEL PHARMACEUTICALS PLC | AGrant or award Stock Option (Right to Buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Mar 4, 2024 |
Questions about Gregory J Divis
Answered from the filings on this page, as of the latest one.
Is Gregory J Divis buying or selling?
Not in the last 12 months. Gregory J Divis's latest open-market trade on SEC Form 4 was bought $100k of AVDL on Dec 6, 2024.
How did Gregory J Divis's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Gregory J Divis has 0.
Where does Gregory J Divis file Form 4?
Gregory J Divis has filed Form 4 at AVDL (AVADEL PHARMACEUTICALS PLC) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.